Study on Safinamide and Rasagiline for Treating Fatigue in Parkinson's Disease Patients on Stable Dopaminergic Treatment

This clinical trial is focused on studying Parkinson's Disease, a condition that affects movement and often includes symptoms like tremors, stiffness, and difficulty with balance and coordination. The study specifically looks at people with Parkinson's Disease who experience persistent fatigue, which is a common symptom that can significantly impact daily life. The trial will compare two treatments: Safinamide and Rasagiline. Both are medications taken orally in tablet form and are used to help manage symptoms of Parkinson's Disease.

The purpose of the study is to evaluate the safety and effectiveness of these two medications in reducing fatigue associated with Parkinson's Disease. Participants will be randomly assigned to receive either Safinamide at a dose of 100 mg per day or Rasagiline at a dose of 1 mg per day. The study will last for 24 weeks, during which time participants will continue their usual Parkinson's treatment while adding one of these medications. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know which medication each participant is receiving, to ensure unbiased results.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. This will include measuring blood pressure, heart rate, and conducting blood tests. Additionally, participants will be assessed using the Movement Disorders Society Unified Parkinson's Disease Rating Scale part III (MDS UPDRS-III), which helps evaluate the severity of Parkinson's symptoms. The study aims to provide valuable information on how these medications can help manage fatigue in people with Parkinson's Disease.